Cytek Biosciences
CTKB
106 hedge funds and large institutions have $428M invested in Cytek Biosciences in 2023 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 54 increasing their positions, 23 reducing their positions, and 13 closing their positions.
504% more call options, than puts
Call options by funds: $344K | Put options by funds: $57K
135% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 23
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
5% more funds holding
Funds holding: 101 → 106 (+5)
0.02% less ownership
Funds ownership: 56.78% → 56.77% (-0.02%)
35% less capital invested
Capital invested by funds: $658M → $428M (-$230M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$22.7M |
| 2 |
BlackRock
New York
|
+$13.2M |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
+$5.62M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.58M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$44M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$10.7M |
| 3 |
MGM
Miura Global Management
New York
|
-$3.25M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.3M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.86M |
CTKB Hedge Fund Activity: Q3 2023 in Review
106 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q3 2023, worth a combined $428M — down 35% from $658M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CTKB positions and 13 closed out — a net gain of 5 holders — while 54 added to existing stakes and 23 trimmed.
The largest buyer was Brown Capital Management, adding an estimated $22.7M. The largest seller was RA Capital Management, cutting an estimated $44M.
- 106 institutional investors held Cytek Biosciences (CTKB) as of Q3 2023, up from 101 in Q2 2023.
- Funds reported $428M of Cytek Biosciences stock for Q3 2023, down 35% quarter-over-quarter.
- 18 funds opened new Cytek Biosciences positions in Q3 2023 and 13 closed out, a net change of +5 holders.
- The largest Cytek Biosciences buyer in Q3 2023 was Brown Capital Management, an estimated $22.7M added.
- The largest Cytek Biosciences seller in Q3 2023 was RA Capital Management, an estimated $44M sold.
Based on aggregated 13F filings for Q3 2023.